50 results
Page 2 of 3
424B5
z08u078
24 Mar 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-1.1
7oclk16s
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-1.1
q27jefd8o
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
uoy qqx1p
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
p7ratdl0ce
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
thqqyro1ts
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
DEF 14A
2stnfm9r4nuu0pap0rb2
26 Apr 19
Definitive proxy
5:02pm